However, contrary to these in vitro studies, CD19 CAR T-cell clinical trials do not indicate a correlation between the degree of target antigen expression and clinical response in lymphoma (43) or multiple myeloma (44). This evidence concerns the gene CD19 and AL amyloidosis.